A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD

被引:4
作者
Thakral, Nimish [1 ]
Desalegn, Hailemichael [2 ]
Diaz, Luis Antonio [3 ]
Cabrera, Daniel [4 ,5 ]
Loomba, Rohit [6 ]
Arrese, Marco [3 ]
Arab, Juan Pablo [3 ,7 ]
机构
[1] Univ Kentucky, Div Gastroenterol & Hepatol, Lexington, KY USA
[2] Western Univ, Schulich Sch Med, Dept Med, Div Gastroenterol, London, ON, Canada
[3] Pontificia Univ Catolica Chile, Escuela Med, Dept Gastroenterol, Santiago, Chile
[4] Univ los Andes, Ctr Invest & Innovac Biomed CiiB, Santiago, Chile
[5] Univ Bernardo OHiggins, Escuela Med, Fac Ciencias Med, Santiago, Chile
[6] Univ Calif San Diego, MASLD Res Ctr, Div Gastroenterol & Hepatol, San Diego, CA USA
[7] Virginia Commonwealth Univ, Sch Med, Div Gastroenterol Hepatol & Nutr, Dept Internal Med, Richmond, VA 23284 USA
关键词
biomarkers; steatosis; MASLD; cirrhosis; precision medicine; FATTY LIVER-DISEASE; MAGNETIC-RESONANCE ELASTOGRAPHY; PREDICTING FIBROSIS STAGE; TRANSIENT ELASTOGRAPHY; NONALCOHOLIC STEATOHEPATITIS; DIAGNOSTIC-ACCURACY; NONINVASIVE DIFFERENTIATION; UNITED-STATES; STEATOSIS; MARKERS;
D O I
10.1055/a-2364-2928
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The new nomenclature of metabolic dysfunction-associated steatotic liver disease (MASLD) emphasizes a positive diagnosis based on cardiometabolic risk factors. This definition is not only less stigmatizing but also allows for subclassification and stratification, thereby addressing the heterogeneity of what was historically referred to as nonalcoholic fatty liver disease. The heterogeneity within this spectrum is influenced by several factors which include but are not limited to demographic/dietary factors, the amount of alcohol use and drinking patterns, metabolic status, gut microbiome, genetic predisposition together with epigenetic factors. The net effect of this dynamic and intricate system-level interaction is reflected in the phenotypic presentation of MASLD. Therefore, the application of precision medicine in this scenario aims at complex phenotyping with consequent individual risk prediction, development of individualized preventive strategies, and improvements in the clinical trial designs. In this review, we aim to highlight the importance of precision medicine approaches in MASLD, including the use of novel biomarkers of disease, and its subsequent utilization in future study designs.
引用
收藏
页码:273 / 286
页数:14
相关论文
共 125 条
[21]   Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease [J].
Cermelli, Silvia ;
Ruggieri, Anna ;
Marrero, Jorge A. ;
Ioannou, George N. ;
Beretta, Laura .
PLOS ONE, 2011, 6 (08)
[22]   Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases [J].
Coco, B. ;
Oliveri, F. ;
Maina, A. M. ;
Ciccorossi, P. ;
Sacco, R. ;
Colombatto, P. ;
Bonino, F. ;
Brunetto, M. R. .
JOURNAL OF VIRAL HEPATITIS, 2007, 14 (05) :360-369
[23]   Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials [J].
Davison, Beth A. ;
Harrison, Stephen A. ;
Cotter, Gad ;
Alkhouri, Naim ;
Sanyal, Arun ;
Edwards, Christopher ;
Colca, Jerry R. ;
Iwashita, Julie ;
Koch, Gary G. ;
Dittrich, Howard C. .
JOURNAL OF HEPATOLOGY, 2020, 73 (06) :1322-1332
[24]   Precision and personalized medicine: What their current definition says and silences about the model of health they promote. Implication for the development of personalized health [J].
Delpierre, Cyrille ;
Lefevre, Thomas .
FRONTIERS IN SOCIOLOGY, 2023, 8
[25]   Global burden of liver disease: 2023 update [J].
Devarbhavi, Harshad ;
Asrani, Sumeet K. ;
Arab, Juan Pablo ;
Nartey, Yvonne Ayerki ;
Pose, Elisa ;
Kamath, Patrick S. .
JOURNAL OF HEPATOLOGY, 2023, 79 (02) :516-537
[26]   Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study [J].
Emdin, Connor A. ;
Haas, Mary ;
Ajmera, Veeral ;
Simon, Tracey G. ;
Homburger, Julian ;
Neben, Cynthia ;
Jiang, Lan ;
Wei, Wei-Qi ;
Feng, Qiping ;
Zhou, Alicia ;
Denny, Joshua ;
Corey, Kathleen ;
Loomba, Rohit ;
Kathiresan, Sekar ;
Khera, Amit, V .
GASTROENTEROLOGY, 2021, 160 (05) :1620-+
[28]   Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [J].
Feldstein, Ariel E. ;
Lopez, Rocio ;
Tamimi, Tarek Abu-Rajab ;
Yerian, Lisa ;
Chung, Yoon-Mi ;
Berk, Michael ;
Zhang, Renliang ;
McIntyre, Thomas M. ;
Hazen, Stanley L. .
JOURNAL OF LIPID RESEARCH, 2010, 51 (10) :3046-3054
[29]   Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes [J].
Fennoun, Halima ;
El Mansouri, Souhaila ;
Tahiri, Mohammed ;
Haraj, Nassim Essabah ;
El Aziz, Siham ;
Hadad, Fouad ;
Hliwa, Wafaa ;
Badr, Wafaa ;
Chadli, Asma .
PAN AFRICAN MEDICAL JOURNAL, 2020, 37 :270
[30]   Accuracy of Real-Time Shear Wave Elastography for Assessing Liver Fibrosis in Chronic Hepatitis C: A Pilot Study [J].
Ferraioli, Giovanna ;
Tinelli, Carmine ;
Dal Bello, Barbara ;
Zicchetti, Mabel ;
Filice, Gaetano ;
Filice, Carlo .
HEPATOLOGY, 2012, 56 (06) :2125-2133